Provided by Tiger Trade Technology Pte. Ltd.

Alumis Inc.

7.16
+0.19002.73%
Post-market: 6.91-0.2500-3.49%19:30 EDT
Volume:1.37M
Turnover:9.75M
Market Cap:923.64M
PE:-1.88
High:7.29
Open:7.04
Low:6.90
Close:6.97
52wk High:31.35
52wk Low:4.28
Shares:129.00M
Float Shares:97.15M
Volume Ratio:0.52
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8005
EPS(LYR):-2.8616
ROE:-93.65%
ROA:-45.34%
PB:2.04
PE(LYR):-2.50

Loading ...

Alumis - Lumus Phase 2B Trial of Envudeucitinib Did not Meet Primary and Secondary Endpoints

THOMSON REUTERS
·
Sep 01

Alumis - Robust Responses in Ifngs-High Subgroup Support Phase 3 Development of Envudeucitinib in Sle

THOMSON REUTERS
·
Sep 01

Alumis - on Track to Submit Nda for Envudeucitinib in Plaque Psoriasis in Q4 2026

THOMSON REUTERS
·
Sep 01

Alumis Announces Topline Results from Envudeucitinib Phase 2B Trial in Systemic Lupus Erythematosus (Sle)

THOMSON REUTERS
·
Sep 01

Alumis Inc. - Actively Evaluating Opportunities to Maximize Value of Our Oral Tyk2 Portfolio

THOMSON REUTERS
·
Sep 01

NASDAQ Trade Halt Halt News Pending at 07:25 Am

Reuters
·
Sep 01

What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders

Simply Wall St.
·
Aug 19

Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases

Reuters
·
Aug 15

Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 15

Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
Aug 14

Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)

TIPRANKS
·
Aug 14

Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate

Benzinga Earnings
·
Aug 14

Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million

Reuters
·
Aug 14

Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027

THOMSON REUTERS
·
Aug 14

Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026

THOMSON REUTERS
·
Aug 14

Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements

Dow Jones
·
Aug 14

Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Alumis reports strong Phase 3 data for envudeucitinib

TIPRANKS
·
Aug 11

Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3

THOMSON REUTERS
·
Aug 11